MCRB SERES THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, SERES THERAPEUTICS INC reported revenue of $736K, net income of $4.58M and diluted EPS of $0.47; over the last four quarters revenue was $1.88M and net income −$22.5M; for the fiscal year ended December 2025 revenue was $789K.
MCRB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $789K, gross profit n/a, operating income −$94.0M, net income $5.70M (margin 721.9%), EPS $0.64
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$121M, net income $136K (margin n/a), EPS $0.00
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$195M, net income −$114M (margin n/a), EPS −$17.77
- Fiscal year ended Dec 2022: revenue $7.13M, gross profit n/a, operating income −$180M, net income −$250M (margin -3509.5%), EPS −$2.31
- Fiscal year ended Dec 2021: revenue $145M, gross profit n/a, operating income −$64.5M, net income −$65.6M (margin -45.2%), EPS −$0.72
MCRB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $736K, net income $4.58M, EPS $0.47
- Quarter ended Mar 31, 2026: revenue $358K, net income −$19.9M, EPS −$2.08
- Quarter ended Dec 31, 2025 (from the annual report): revenue $438K, net income −$15.3M, EPS −$1.78
- Quarter ended Sep 30, 2025: revenue $351K, net income $8.20M, EPS $0.94
- Quarter ended Jun 30, 2025: revenue $0, net income −$19.9M, EPS −$2.27
- Quarter ended Mar 31, 2025: revenue $0, net income $32.7M, EPS $3.75
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (up 100.0% year over year), net income −$15.6M, EPS −$1.80
- Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income $88.8M, EPS $11.63
- Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$32.9M, EPS −$4.34
- Quarter ended Mar 31, 2024: revenue $0 (up 100.0% year over year), net income −$40.1M, EPS −$5.49
- Quarter ended Dec 31, 2023 (from the annual report): revenue −$126M (down 13049.8% year over year), net income −$41.2M, EPS −$17.19
- Quarter ended Sep 30, 2023: revenue $310K (down 91.0% year over year), net income −$47.9M, EPS −$0.37
- Quarter ended Jun 30, 2023: revenue $126M (up 10300.7% year over year), net income $46.6M, EPS $0.36
- Quarter ended Mar 31, 2023: revenue −$522K (down 135.0% year over year), net income −$71.2M, EPS −$0.57
- Quarter ended Dec 31, 2022 (from the annual report): revenue $975K (down 86.5% year over year), net income −$68.8M, EPS −$0.51
- Quarter ended Sep 30, 2022: revenue $3.44M (down 97.3% year over year), net income −$60.0M, EPS −$0.49
- Quarter ended Jun 30, 2022: revenue $1.22M (down 76.9% year over year), net income −$64.7M, EPS −$0.70
- Quarter ended Mar 31, 2022: revenue $1.49M (down 73.9% year over year), net income −$56.6M, EPS −$0.61
- Quarter ended Dec 31, 2021 (from the annual report): revenue $7.22M, net income −$50.0M, EPS −$0.52
- Quarter ended Sep 30, 2021: revenue $127M, net income $68.2M, EPS $0.72
MCRB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $1.12M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$149M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$117M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$229M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $6.69M, share buybacks n/a
MCRB balance sheet
- Jun 30, 2026: cash $15.6M, total assets $102M, total liabilities $67.1M, shareholders' equity $34.5M
- Mar 31, 2026: cash $29.8M, total assets $118M, total liabilities $91.1M, shareholders' equity $26.5M
- Dec 31, 2025: cash $45.8M, total assets $138M, total liabilities $94.0M, shareholders' equity $44.2M
- Sep 30, 2025: cash $47.6M, total assets $143M, total liabilities $99.8M, shareholders' equity $43.7M
- Jun 30, 2025: cash $45.4M, total assets $144M, total liabilities $111M, shareholders' equity $33.0M
- Mar 31, 2025: cash $58.8M, total assets $164M, total liabilities $114M, shareholders' equity $50.5M
- Dec 31, 2024: cash $30.8M, total assets $140M, total liabilities $126M, shareholders' equity $13.8M
- Sep 30, 2024: cash $66.8M, total assets $179M, total liabilities $155M, shareholders' equity $23.9M
What is MCRB's revenue?
SERES THERAPEUTICS INC reported $1.88M of revenue over its last four quarters, through June 30, 2026.
Is MCRB profitable?
No. SERES THERAPEUTICS INC lost $22.5M over the last four quarters.
What is MCRB's EPS?
Diluted earnings per share over the last four quarters were −$2.45; $0.47 in the latest quarter.